【All Cosmos Bio-Tech (KY)】Announcement of the Company's Board of Directors' Approval of the Q1 2026 Consolidated Financial Report

Key facts

  • 【All Cosmos Bio-Tech (KY)】Announcement of the Company's Board of Directors' Approval of the Q1 2026 Consolidated Financial Report
  • All Cosmos Bio-Tech (KY) announced that its Board of Directors approved the consolidated financial report for the first quarter of 2026. This report details the key financial performance for the period from January 1 to March 31, 2026.
  • Source: PR Times
  • Date: May 13, 2026

Direct answer

All Cosmos Bio-Tech (KY) announced that its Board of Directors approved the consolidated financial report for the first quarter of 2026. This report details the key financial performance for the period from January 1 to March 31, 2026.

Citation
【All Cosmos Bio-Tech (KY)】Announcement of the Company's Board of Directors' Approval of the Q1 2026 Consolidated Financial Report (May 13, 2026), PR Times
Source
PR Times
Date
May 13, 2026
All Cosmos Bio-Tech (KY) announced that its Board of Directors approved the consolidated financial report for the first quarter of 2026. This report details the key financial performance for the period from January 1 to March 31, 2026.
調査NQ 0/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: May 13, 2026 at 09:00
  • 🔍 Collected: May 14, 2026 at 08:00 (23h 0m after Published)
  • 🤖 AI Analyzed: May 14, 2026 at 10:00 (1h 59m after Collected)
1. Date of Board of Directors' resolution or approval: 2026/05/13
2. Date of Audit Committee approval: 2026/05/13
3. Reporting period of financial report or annual self-audited financial information (XXX/XX/XX~XXX/XX/XX): 2026/01/01~2026/03/31
4. Cumulative operating revenue from January 1 to the end of this period (in thousands): 527,663
5. Cumulative operating gross profit (loss) from January 1 to the end of this period (in thousands): 147,176
6. Cumulative operating income (loss) from January 1 to the end of this period (in thousands): 26,408
7. Cumulative net profit (loss) before tax from January 1 to the end of this period (in thousands): 35,978
8. Cumulative net profit (loss) for this period from January 1 to the end of this period (in thousands): 14,708
9. Cumulative net profit (loss) attributable to owners of the parent company from January 1 to the end of this period (in thousands): 5,266
10. Basic earnings per share (loss) from January 1 to the end of this period (in NTD): 0.08
11. Total assets at period end (in thousands): 4,254,103
12. Total liabilities at period end (in thousands): 818,221
13. Equity attributable to owners of the parent company at period end (in thousands): 2,734,995
14. Other matters that should be stated: None.

FAQ

What are the key facts in this article?

All Cosmos Bio-Tech (KY) announced that its Board of Directors approved the consolidated financial report for the first quarter of 2026. This report details the key financial performance for the period from January 1 to March 31, 2026.

What is the direct answer?

All Cosmos Bio-Tech (KY) announced that its Board of Directors approved the consolidated financial report for the first quarter of 2026. This report details the key financial performance for the period from January 1 to March 31, 2026.

What is the source and date?

PR Times: https://mops.twse.com.tw/material/twse-4148-2026-05-13-e1bc4c53 | May 13, 2026